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Introduction {#sec1}
============

High blood triglyceride (TG) level is one of the leading risk factors for coronary artery diseases (CADs) ([@bib2], [@bib17]), along with low-density lipoprotein cholesterol (LDL-C). Human genetic studies have suggested that high TG levels causally affect the risk of CADs independent of LDL-C and high-density lipoprotein cholesterol (HDL-C) ([@bib6]). In addition, diabetes mellitus and metabolic syndrome are two major risk factors for CADs ([@bib26]). High blood TG level linked to insulin resistance is a phenotype common to these metabolic diseases. Thus, lowering blood TG level could further reduce the incidence of CADs as well as type 2 diabetes and metabolic syndrome, especially in high-risk individuals. Apolipoprotein (Apo) C3 and angiopoietin-like 3 (ANGPTL3) are two molecular targets currently under intensive studies for lowering blood TG ([@bib29], [@bib34], [@bib50]). The two targets share the common mechanism of inhibition of lipoprotein lipase (LPL) ([@bib20], [@bib21], [@bib32]). Finding other targets independent of LPL could further lower blood TG levels.

Endoplasmic reticulum (ER)-degradation alpha-mannosidase like protein 3 (EDEM3) plays a crucial role in the ER-associated degradation (ERAD) pathway ([@bib7], [@bib15], [@bib31]). Nascent polypeptides emerging in the ER undergo several quality control processes assisted by ER chaperones and folding factors that ensure proper folding and maturation. Misfolded or unassembled proteins are recognized and subject to degradation ([@bib4], [@bib14], [@bib44]). The ER-resident EDEM family of proteins is responsible for identifying misfolded proteins, trimming the mannoses of their N-linked glycans, and signaling them for degradation. It was reported that all the EDEM members have mannosidase activity ([@bib15], [@bib16], [@bib41]). It is unclear how EDEM3 specifically recognizes the misfolded proteins. Previous findings have indicated that the enzymatic activity of EDEM3 does not necessarily target only misfolded glycoproteins, as it has been shown to stimulate mannose trimming among the total glycoproteins under the condition of EDEM3 overexpression ([@bib15]). The biological significance of EDEM3 is still unknown.

We provide evidence that EDEM3 may be another TG-lowering target that represents a distinct mechanism in modulating TG metabolism. We identified a rare variant (P746S) in the coding region of EDEM3 using human genetic studies that is specifically associated with lower blood TG. Deletion of EDEM3 gene in two types of human hepatoma HepG2 and Huh7 cells strongly increased the uptake of very-low-density lipoprotein (VLDL) as a result of increased LRP1 expression. Consistent with this observation, knockdown (KD) of hepatic EDEM3 with CRISPR/Cas9 decreased the plasma TG level in mice. Interestingly, we found that EDEM3 gene deletion increased the cell surface mannose presence without increasing the sensitivity of the cells to ER stress, likely due to the compensation by increased RNA processing and ER protein transport, and repressed cellular metabolic processes. Importantly, the cellular lipid metabolite profile under EDEM3 gene deletion largely explains the plasma lipid metabolite results from the individuals carrying the EDEM3 missense variant, P746S. Thus, our findings show that by regulating LRP1 expression, EDEM3 is able to modulate the plasma TG level. Inhibition of EDEM3 expression could offer an alternative path to lower TG levels.

Results {#sec2}
=======

A Missense Mutation in EDEM3 Is Linked to Lower Human Plasma TG Levels {#sec2.1}
----------------------------------------------------------------------

To investigate possible roles of EDEM3 in lipoprotein metabolism, we first took a human genetic approach to identify EDEM3 single-nucleotide polymorphisms (SNPs) that might be associated with lipid traits. Common variants near EDEM3 have not been associated with blood TGs in the population ([Figure S1](#mmc1){ref-type="supplementary-material"}) ([@bib46]). We analyzed \>300,000 individuals of mainly European ancestry with exome array genotyping available from the Global Lipids Genetics Consortium against plasma lipid levels ([@bib23]). There are many rare variants associated with TG levels ([@bib23]). In the full analysis of exome array variation, we found 142 variants associated with TG levels at an alpha level of 0.0001 and a minor allele frequency less than 5%. Among seven EDEM3 SNPs examined, only one, rs7844298 (P746S), shows statistically significant relations with lower plasma TG level, but not with HDL-C and LDL-C ([Table S1](#mmc1){ref-type="supplementary-material"} and [Figure 1](#fig1){ref-type="fig"}A). Comparing this SNP with other validated missense variants shows that its effect on TG level is \~65% of ANGPTL3 rs77871363 (M259T) and \~38% of PCSK9 rs28362286 (gain-of-function), both of which exhibit the strong link with TG phenotypes ([Figure 1](#fig1){ref-type="fig"}B). The SNP is located at the coding region of EDEM3 protease-associated (PA) domain ([Figure 2](#fig2){ref-type="fig"}C), which is not present in other EDEM members ([@bib31]). The SNP\'s unique domain location and its effect on blood TG concentrations at the population level suggest that EDEM3 may have an unknown mechanism in regulating lipoprotein metabolism.Figure 1Genetic Association Study of EDEM3 Missense Mutations with Lipid Phenotypes(A) Significant association of EDEM3 SNP rs78444298 (P746S) with blood TG (5% decrease; p = 1.2 × 10^−5^), but not with LDL-C and HDL-C (p \> 0.05).(B) Comparison of the effect of *EDEM3* rs78444298 with other missense mutations of TG genes including *ANGPTL3* rs77871363, *PCSK9* rs28362286 (gain-of-function), and *NCP1L1* rs35803101 (negative control) on plasma TG. Beta, which represents the effect size of variant association on log(TG), is displayed in standard deviation units of log(TG).Figure 2Confirmation of EDEM3 Gene Deletion in HepG2 and Huh7 Cells(A and B) Western analysis of EDEM3 expression. Extracts from EDEM3 WT and KO HepG2 (A) and Huh7 (B) cells were examined with western blotting and probed with anti-EDEM3 and anti-β-actin antibodies.(C) Domain similarity of Class I α1,2-mannosidase family members. The conserved mannosidase homology domain, the unique protease-associated (PA) domain, and ER retrieval signal of EDEM3 are highlighted. The positions of sgRNAs and the human EDEM3 P746S mutation are indicated.

Deletion of EDEM3 Gene Strongly Increased VLDL, but Not LDL, Uptake {#sec2.2}
-------------------------------------------------------------------

It is likely that the lower plasma TG level observed in human genetic studies is from the damaging effect of the mutation on the cellular activity of EDEM3. Therefore, to obtain the mechanistic insight of EDEM3 function in lipid metabolism, we tried to delete the gene in human hepatoma cells for functional assays. We used CRISPR/cas9 genome editing system with three single guide RNAs (sgRNAs) that target the exon region of EDEM3 gene ([Figure 2](#fig2){ref-type="fig"}B) along with scramble control sgRNAs ([@bib39], [@bib40]). After screening several hundreds of clones, we obtained EDEM3 knockout (KO) Huh7 and HepG2 cells as well as the scramble controls (wild-type \[WT\]). Western analysis confirms the deletion of EDEM3 gene specifically in three HepG2 and Huh7 KO clones ([Figures 2](#fig2){ref-type="fig"}A and 2B).

The lower TG phenotypes caused by the EDEM3 mutation could be due to enhanced uptake of TG-rich lipoproteins (TGLs), reduced secretion of VLDL, or both. We first tested whether the EDEM3 gene deletion might affect the VLDL uptake. The KO and control Huh7 and HepG2 clones were incubated with human Dil-VLDL ([@bib42]). We found that EDEM3 deficiency strongly increased the VLDL uptake in both Huh7 (by 1.6 times) and HepG2 (by \~5.2 times) cells ([Figure 3](#fig3){ref-type="fig"}). Dramatic increases were observed in some HepG2 and Huh7 KO clones (by \~2.6 and \~10 times, respectively) ([Figures 3](#fig3){ref-type="fig"}A and 3B, bottom images). Similar assays with human Dil-LDL were performed, but no significant changes were observed ([Figure S2](#mmc1){ref-type="supplementary-material"}). Consistent with this, we found that the EDEM3 KO did not significantly change the LDLR expression ([Figure S3](#mmc1){ref-type="supplementary-material"}). The data suggest that deletion of EDEM3 gene increases VLDL, but not LDL, uptake.Figure 3Deletion of *EDEM3* Gene Strongly Enhanced Dil-VLDL Uptake(A and B) (A) Three individual EDEM3 scramble control (WT) and KO HepG2 (A) and Huh7 (B) clones were incubated with Dil-VLDL. Top, Representative images of the uptake assays from *EDEM3* KO and control cells. Bottom, Quantification of the uptake assays from three clones of the control cells (\~200 cells) and KO cells (\~500 cells). Cellular Dil-VLDL particle areas were quantified using ImageJ. p values (t test) were calculated by comparing the KO cells with the control cells. The error bars represent standard error of the mean (SEM) in the figure. ∗p \< 0.05; ∗∗p \< 0.01. Scale bar, 25 μm.

Deletion of EDEM3 Gene Did Not Affect VLDL Secretion {#sec2.3}
----------------------------------------------------

We next investigated whether EDEM3 gene deletion might also affect the VLDL or nascent ApoB secretion. To this end, we carried out time course experiments to monitor nascent ApoB-100 secretion and its accumulation in culture media. Three clones of EDEM3 KO and control HepG2 and Huh7 cells were washed and incubated with fresh media. At various time points, fractions of the media were analyzed with ApoB ELISA. The ApoB in the media reflects the dynamics of ApoB secretion from and uptake into the cells. However, at the earliest time points (i.e., 20 and 40 min), the ApoB in the media most likely represents the nascent ApoB secreted from the cells. We found no significant difference (p \> 0.05) in the ApoB levels between the KO and control clones in both HepG2 and Huh7 cells at 20 and 40 min time points ([Figures 4](#fig4){ref-type="fig"}A and 4B). We then monitored the ApoB concentrations from Huh7 cells for longer period. After 40 min, the ApoB level in the media of Huh7 cells decreased at various time points and became significantly decreased (p \< 0.05) for all the KO clones at 8 h ([Figure 4](#fig4){ref-type="fig"}C). Because EDEM3 gene deletion did not affect the ApoB secretion, the increased uptake is most likely responsible for all the decreases of the ApoB in the media. These data are consistent with those from the Dil-VLDL uptake assays, indicating that enhanced VLDL uptake might play a major role in reducing the TG level under EDEM3 deficiency.Figure 4Deletion of *EDEM3* Gene Reduced ApoB-100 Accumulation in Culture Media without Interfering with Nascent ApoB Secretion(A and B) Three individual EDEM3 scramble control (WT) and KO HepG2 (A) and Huh7 (B) clones were used for time course experiments to monitor ApoB presence in culture media between 20 and 40 min using ApoB ELISA kit.(C) Complete time course experiment for monitoring culture media ApoB concentrations from Huh7 cells between 20 min and 8 hp values (t test) were calculated by comparing the KO cells with the control cells. The error bars represent SEM in the figure. ∗p \< 0.05; ∗∗p \< 0.01.

Deletion of EDEM3 Gene Increased LRP1 Expression {#sec2.4}
------------------------------------------------

In addition to LDLR ([Figure S3](#mmc1){ref-type="supplementary-material"}), there are several other receptors including LRP1 and VLDL receptor (VLDLR) that could be potentially linked to the phenotypes we observed. It should be noted that the expression of VLDLR is low or undetectable in the livers ([@bib30]), and most importantly, the VLDLR KO mice did not display any lipoprotein defects ([@bib8]). In contrast, hepatic LRP1 was shown to play a central role in clearance of TGLs such as chylomicron and VLDL remnants ([@bib22], [@bib37], [@bib48], [@bib47]). Previous study also validated that LRP1 is modified with N-linked glycans ([@bib28]) and is likely to be the target of EDEM3 in the ER. It is possible that EDEM3 modulates the plasma TG level by regulating the LRP1 expression in the livers. To test this hypothesis, we first used indirect immunofluorescence to examine the cell surface LRP1 expression. The EDEM3 WT and KO HepG2 and Huh7 clones were stained with anti-LRP1 and anti-ApoB antibodies ([@bib49]). The results presented in [Figure 5](#fig5){ref-type="fig"} show that deletion of EDEM3 gene substantially increased the cell surface LRP1 expression both in HepG2 and Huh7 cells. In the WT control cells, the cell surface LRP1 is barely detectable under the conditions we tested. However, in the KO cells, the LRP1 signal is strongly increased (by \~1.7 times and \~3.5 times increases in HepG2 and Huh7 cells, respectively). The accumulated LRP1 on the cell surface can be clearly seen at the cell peripheries in the flatter KO Huh7 cells ([Figure 5](#fig5){ref-type="fig"}B).Figure 5Deletion of *EDEM3* Gene Increased LRP1 Expression(A) Three individual EDEM3 scramble control (WT) and KO HepG2 (A) and Huh7 (B) clones were stained with anti-LRP1 and anti-ApoB antibodies and analyzed with confocal microscope (left). Images were quantified with ImageJ from 100--200 cells for each clone (right). p values (t test) were calculated by comparing the results from the KO cells with those from the control cells. The error bars represent SEM in the figure. ∗p \< 0.05; ∗∗p \< 0.01. Scale bar, 25 μm.

We then examined the LRP1 expression with western analysis. Consistent with the above-mentioned immunofluorescence results ([Figure 5](#fig5){ref-type="fig"}), it shows that the LRP1 protein level is indeed greatly increased in the EDEM3 KO HepG2 and Huh7 cells ([Figures 6](#fig6){ref-type="fig"}A and 6B). Interestingly, we observed that the LRP1 from the KO cells has slower mobility, which is more obvious from the HepG2 KO cells ([Figure 6](#fig6){ref-type="fig"}A, lanes 4--6), indicating that the LRP1 may possess post-translational modification changes related to the activity of EDEM3 in the ER. Although we detected the increased LRP1 expression, the mobility changes of LRP1 from those of Huh7 KO cells were barely detectable ([Figure 6](#fig6){ref-type="fig"}B). It was reported that LRP1 is differentially glycosylated in a tissue-specific manner ([@bib28]). We reasoned that the LRP1 mobility changes might be related to cell types. Because of mannose hydrolase activity of EDEM3, we expected that the LRP1 in the KO cells might retain mannose/glucose, which are supposed to be removed in the ER ([@bib31]). To test this, the EDEM3 WT and KO HepG2 clones were stained with fluorescein isothiocyanate-labeled concanavalin A (ConA) (recognizing mannose) and analyzed with flow cytometry. The results show that the KO cells indeed contained stronger signal than the WT cells ([Figure 6](#fig6){ref-type="fig"}C). Thus, the data shown here suggest that deletion of EDEM3 gene increases the cell surface LRP1 expression, which is most likely related to its post-translational processing in the ER.Figure 6Deletion of *EDEM3* Gene Increased LRP1 Expression as well as cell Surface Mannose-Containing Proteins(A and B) Extracts from three individual EDEM3 scramble control (WT) and KO HepG2 (A) and Huh7 (B) clones were analyzed with western blotting and probed with anti-LRP1 and anti-β-actin antibodies.(C) The WT and KO HepG2 clones as in (A) were stained with fluorescein isothiocyanate-ConA and fixed with 1% paramaldehyde. The cells were then analyzed with flow cytometry.

Complement of EDEM3 Deletion with WT, but Not P746S Mutant, EDEM3 Reduced LRP1 Expression and VLDL Uptake {#sec2.5}
---------------------------------------------------------------------------------------------------------

To obtain further functional evidence of EDEM3 in regulating LRP1 expression and VLDL uptake, we performed complementary analysis of EDEM3 deletion with WT and P746S mutant EDEM3. The *EDEM3* KO HepG2 and Huh7 cells were infected with control lentivirus alone or the lentiviruses harboring the cDNAs of FLAG-tagged WT and P746S mutant *EDEM3*. We focused on the LRP1 from HepG2 cells because it generated more mobility changes ([Figure 6](#fig6){ref-type="fig"}A). Western analysis ([Figure 7](#fig7){ref-type="fig"}A, middle) confirmed the expression of the WT ([Figure 7](#fig7){ref-type="fig"}A, middle, lanes 4--6) and mutant (lanes 7--9) *EDEM3*. The expression of WT EDEM3 significantly reduced the level of LRP1 (by \~11%). In contrast, the mutant *EDEM3* even increased the LRP1 expression by \~74%. The LRP1 from the KO cells with WT EDEM3 complement had slightly faster mobility when compared with those from the KO cells and the cells with the mutant EDEM3 (more obvious for the smaller fragment \[sLRP1\] of LRP1, compare lanes 4--6 with lanes 3 or 7), indicating modification changes. Immunofluorescence analysis confirmed the LRP1 expression changes in the KO HepG2 cells and the cells with the WT and mutant EDEM3. The increased LRP1 expression correlated with the elevated cellular ApoB signal ([Figure S4](#mmc1){ref-type="supplementary-material"}). Similar results were also obtained from the Huh7 KO with the WT and mutant EDEM3 ([Figure S5](#mmc1){ref-type="supplementary-material"}).Figure 7Complementary Analysis of *EDEM3* Gene Deletion with WT and P746S Mutant EDEM3(A) EDEM3 KO HepG2 cells were infected with control lentivirus or the same virus containing WT and P746S EDEM3 cDNAs**.** Extracts from the complementary or control cells were analyzed with western blotting and probed with the antibodies against LRP1, EDEM3, and GAPDH (from top to bottom). sLRP1 is likely a smaller fragment of LRP1.(B) Normalized quantification of LRP1 expression with GAPDH as in (A). p values (t test) were calculated by comparing the KO + WT cells with the KO or KO + P746S cells.ANOVA p value \< 0.001. The error bars represent SEM in the figure. ∗p \< 0.05; ∗∗p \< 0.01.

The above-mentioned cells were then used for VLDL uptake assays. The complementary expression of WT EDEM3 drastically reduced the VLDL uptake (by \~62%) when compared with those of the KO HepG2 cells. In contrast, the expression of the mutant EDEM3 in the KO cells increased the VLDL uptake (by nearly two times) when compared with the WT complement ([Figure S6](#mmc1){ref-type="supplementary-material"}). Again, similar results were obtained from Huh7 KO cells and the cells with complementary WT (decreased by \~28%) and mutant (increased by \~57%) EDEM3 expressions ([Figure S7](#mmc1){ref-type="supplementary-material"}). Given the crucial roles of LRP1 in regulating TG metabolism ([@bib22]), the increased expression levels of LRP1 most likely explain the elevated VLDL uptakes in both cell types. Therefore, the aforementioned results highlight the role of EDEM3 in regulating LRP1 post-translational processing, and deletion of EDEM3 gene or the loss-of-function mutation facilitates the processing and transport of LRP1 to the cell surface.

Hepatic EDEM3 KD in Mice Increased LRP1 Expression and Essentially Reduced Plasma TG Level {#sec2.6}
------------------------------------------------------------------------------------------

To obtain *in vivo* evidence for the regulation of EDEM3 in LRP1 expression, we knocked down EDEM3 expression in mouse livers using CRISPR/Cas9 genome editing system ([@bib35]). We selected one sgRNA by *in vitro* screening a pool of sgRNAs that target EDEM3 exon 1 (see [Methods](#sec4){ref-type="sec"}). The sgRNA was cloned into a single vector adeno-associated virus (AAV)-Cas9 system containing *Staphylococcus aureus* Cas9 (SaCas9). The viral constructs containing the EDEM3 sgRNA and a non-specific scramble sgRNA (control) were then used for AAV production. The AAV preparations were injected in WT female mice followed by high-fat diet.

Western analysis shows that the CRISPR-based KD reduced the hepatic EDEM3 expression (by \~50%) ([Figure 8](#fig8){ref-type="fig"}A, top and 8B, left). Also, the EDEM3 KD essentially reduced the plasma TG level on days 18 and 27 (by \~43% and \~29%, respectively) ([Figures 8](#fig8){ref-type="fig"}C and 8D). The higher plasma TG observed at days 18 and 27 in the control mice was likely induced by the high-fat diet. The TG reduction suggests that inhibition of EDEM3 might be able to decrease the diet-induced high TG level. Consistent with the above-mentioned results, EDEM3 KD significantly increased (by \~50%) the expression of hepatic LRP1 ([Figure 8](#fig8){ref-type="fig"}A, middle and 8B, right). Thus, we provide both *in vitro* and *in vivo* evidences that EDEM3 inhibition increases the expression of LRP1, which in turn increases the TGL uptake and reduces the plasma TG level.Figure 8Hepatic *EDEM3* KD Increased LRP1 Expression and Reduced the Plasma TG Level in Mice(A) Liver extracts from the female mice injected with the control AAV or the AAV for EDEM3 CRISPR KD were analyzed with western blotting and probed with anti-EDEM3, anti-LRP1, and anti-GAPDH antibodies (from top to bottom).(B) Quantification of EDEM3 and LRP1 expression normalized with GAPDH as in (A).(C and D) Measurement of the plasma TG levels from the mice injected with the AAVs as in (A). (C) Individual mouse plasma TG levels; (D) average plasma TG of the control and EDEM3 KD groups. p values (t test) were calculated by comparing the KD mice with the corresponding control mice.The error bars represent SEM in the figure. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001.

EDEM3 Deletion Increased the Expression of the Genes Required for RNA and Protein Processing and Transport {#sec2.7}
----------------------------------------------------------------------------------------------------------

EDEM3 functions in protein quality control in the ER ([@bib31]). Deletion of EDEM3 gene might affect the sensitivity of cells to ER stress. To test this, we treated EDEM3 KO and control HepG2 cells with tunicamycin, a reagent known to induce ER stress ([@bib12]). The results ([Figure S8](#mmc1){ref-type="supplementary-material"}) show that the treatment did not induce cell viability changes between the KO and control clones. We observed slightly more cell deaths only in one clone at the highest concentration of tunicamycin. Thus, the deficiency of EDEM3 might not add too much burden on protein processing in the ER.

It is likely that the KO cells might adapt some gene expression changes that enable them to tolerate the deficiency of EDEM3. To investigate this, we performed RNA sequencing (RNA-seq) analysis on the total RNA from the EDEM3 KO and WT HepG2 clones. Differential gene expression analysis shows that the EDEM3 gene deletion induced down-regulation of expression of a large number of genes ([Figure 9](#fig9){ref-type="fig"}A). The down-regulated gene expression resulted in reduced activities of many cellular metabolic pathways such as PPAR signaling, drug metabolism, and protein digestion and absorption ([Figure 9](#fig9){ref-type="fig"}B). Importantly, the pathway analyses show that the expression of the genes for RNA and protein processing and transport are up-regulated ([Figures 9](#fig9){ref-type="fig"}C and 9D). Thus, the up- and down-regulated pathways may directly alleviate the burden potentially resulting from the loss of EDEM3 protein in the ER and facilitate the LRP1 post-translational processing in the ER and transport on the cell surface.Figure 9Deletion of *EDEM3* Gene in HepG2 cells Increased RNA and ER Protein Processing and Transport(A--C) Total RNA from three individual EDEM3 scramble control (WT) and KO HepG2 clones was analyzed with RNA-seq for differential gene expression (A). The down-regulated (B) and up-regulated (C and D) pathways related to EDEM3 gene deletion are shown.

Plasma Metabolite Profile of rs78444298 (EDEM3 P746S) Corresponds to the Cellular Metabolite Pattern of EDEM3 Gene Deletion {#sec2.8}
---------------------------------------------------------------------------------------------------------------------------

To investigate the lipid metabolite changes resulting from EDEM3 gene deletion, we used mass spectrometry to analyze the total lipid extracts from the EDEM3 KO and control HepG2 cells as previously reported ([@bib27], [@bib50]). The results show that the gene deletion induced the accumulation of some diglycerides (DGs) and shorter-carbon-chain TGs ([Figures 10](#fig10){ref-type="fig"}A and 10B). For longer-carbon-chain TGs, some of them increased, whereas others decreased; however, if the cellular metabolite abundance is taken into consideration, there is still accumulation of the longer-carbon-chain TGs ([Figure 10](#fig10){ref-type="fig"}A). For instance, there are extremely low levels of C58:10 and C58:11 TGs. These TGs are much less abundant than the elevated TGs including C50:3, C52:1, C54:1, C54:2, C56:2, and C56:3. There is no significant change for the most abundant C52:2 TG.Figure 10Comparison of the Lipid Metabolite Profiles of rs78444298 (EDEM3 P746S) Framingham Heart Study (FHS) Individuals with Those from *EDEM3* Gene Deletion in HepG2 Cells(A and B) Total cellular lipid extracts from three individual EDEM3 scramble control (WT) and KO HepG2 clones were analyzed with mass spectrometry. The metabolite profile was obtained by comparing the DG and TG abundances (A) and ratios (B) between the WT and KO cells.(C) The association of plasma lipid metabolite profiles in 1,797 individuals from FHS with rs78444298 (P746S) from FHS 1000 Gemomes genome-wide association study cohorts.

We next examined the plasma lipid metabolite changes by SNP rs78444298 genotype (G \> A; 1.5% minor allele frequency) in 1,797 individuals from the Framingham Heart Study with 1000 Genomes imputated genotypes ([@bib36]). The results demonstrate a similar, but in opposite direction, pattern of DGs and shorter-carbon-chain TGs when compared with those from EDEM3 gene deletion ([Figures 10](#fig10){ref-type="fig"}B and 10C). More decreases were found for the longer-carbon-chain TGs. The longer and abundant TGs (C50:3, C52:1, C54:2, and C56:3), which were accumulated in the EDEM3 KO HepG2 clones, are negatively associated with the number of A alleles an individual carried, that is, as we modeled rs78444298 genotypes additively, individuals with the AG genotype have, on average, lower TG metabolites than the individuals with the GG genotype and individuals with the AA genotype have TG metabolites lower, on average, than individuals with the AG genotype. Thus, in general the plasma lipid metabolite profile with increasing number of A alleles is correlated with the corresponding pattern change of the EDEM3 gene deletion, in particular for those DGs and shorter-carbon-chain TGs. The decreased DGs and TGs might result from the increased uptake by the livers because of elevated LRP1 expression induced by the LoF EDEM3 mutation. However, more *in vivo* studies are needed to explore the lipid metabolic changes.

Discussion {#sec3}
==========

We demonstrate that an EDEM3 variant, P746S, is significantly associated with the lower blood TG level using human genetic data. We sought to use a cell-based functional approach by deleting the EDEM3 gene in human hepatoma cells to obtain mechanistic insight for this association. We found that the gene deletion strongly induced the uptake of VLDL as a result of up-regulated LRP1 expression. Hepatic EDEM3 KD in mice further confirmed the results *in vivo*. RNA-seq analyses reveal that the gene deletion up-regulated the pathways for RNA and ER protein processing, which likely facilitated the LRP1 processing in the ER and transport to the cell surface. Furthermore, our metabolomics data show that the cellular lipid metabolite profile is largely consistent with the counterpart association of the missense variant in the plasma of individuals from the population, suggesting that our functional analyses largely explain the phenotype from the genetic association. Collectively, we identified EDEM3 as a regulator in modulating plasma TGs via its activity in the ER, and thus it may represent a potential therapeutic target for TG lowering.

Blood TG level represents the TG content of TGLs in circulation, mainly including the remnants of chylomicron from dietary intake and VLDL secreted from the livers. Blood TG is associated with dietary fat intake, genetic determinants, and physical activity, as well as other factors. There are several drugs available for the treatment of hypertriglyceridemia such as niacin, fibrates, and omega-3-fatty acids ([@bib5], [@bib13], [@bib33]), but none of them is specific. Finding targets for lowering TG and further using them for drug development have lagged behind the drug development for LDL-C lowering. Recent human genetic studies have identified ApoC3 and ANGPTL3 as two important TG targets ([@bib18], [@bib29], [@bib43]) Inhibition of ApoC3 and ANGPTL3 showed strong effects in lowering the blood TG ([@bib9], [@bib10], [@bib50]). However, the two targets share a similar mechanism in modulating the blood TG, i.e., the inhibition of LPL. As mentioned earlier, the three top LDL-C-lowering drugs, statin, ezetimibe, and the PCSK9 inhibitor, cover the hepatic cholesterol synthesis, intestinal cholesterol absorption, and LDL uptake, respectively ([@bib1]). Combination use of these drugs will provide great strength for treatment of complex hyperlipidemia, which cannot be controlled by a single therapeutic agent. Thus, the finding of EDEM3 and its role in modulating blood TG via regulating LRP1 expression would complement the current TG-lowering therapeutic efforts.

EDEM3 modulates the plasma TG by regulating LRP1 expression, which is consistent with the role of LRP1 in regulating TG metabolism ([@bib22]). In contrast to the LDLR, which binds to ApoB-100 as well as ApoE, LRP1 mediates the hepatic uptake of the TGLs mainly through its binding with ApoE, which is present in both chylomicrons and VLDL ([@bib3], [@bib25]). It was observed that genetic defects of LDLR both in humans and mice cause hypercholesterolemia by reducing the uptake of cholesterol-rich LDL, but the clearance of TGLs is not affected ([@bib19], [@bib38]). High plasma TG was only observed when the LRP1 expression is inactivated under LDLR deficiency ([@bib37], [@bib47]). Although the mechanisms for LRP1 and LDLR in regulating TG metabolism remain to be determined ([@bib37]), the existing data suggest that LRP1 plays a major role in the clearance of TGLs.

EDEM3 likely regulates LRP1 expression in a post-transcriptional manner because our RNA-seq analysis did not show significant differences in LRP1 mRNA transcript levels between the EDEM3 WT and KO cells ([Figure 9](#fig9){ref-type="fig"}). It was previously shown that all the LDLR family members including LRP1 possess N-linked glycosylation ([@bib28]). LRP1 is differentially glycosylated apparently only with N-linked glycans in a tissue-specific manner. Although the extent and distribution of the differential glycosylations are largely unknown, it may explain the difference of mobility changes of the LRP1 proteins from HepG2 and Huh7 EDEM3 KO cells ([Figures 6](#fig6){ref-type="fig"}A and 6B). The mannose-containing N-linked glycans are co-translationally added to the nascent receptor polypeptides, which serves as signals recognized by the ER-resident chaperones and folding factors to ensure proper maturation. The unrecoverable misfolded polypeptides undergo mannose trimming by the GH47 family mannosidases including EDEM1, 2, and 3 and are then eventually translocated from the lumen of the ER into the cytoplasm for degradation. EDEM proteins play important roles in maintaining protein folding efficiency by facilitating the extraction of misfolded glycoproteins and accelerating the onset of their degradation.

It is intriguing that the EDEM3 deficiency increases the cell surface LRP1 expression. It could be speculated that EDEM3 deficiency may accelerate the processing and transport of LRP1 from the ER. The acceleration may rely on the N-linked glycan of LRP1 and the α1,2 mannosidase activity of EDEM3, which trim the α(1,2) mannoses of the glycans ([@bib15]), a crucial step in determining the fate of misfolded proteins between productive folding and degradation ([@bib31]). Under EDEM3 deficiency, the LRP1 may carry more mannose moieties at the N-linked glycans, which may allow the LRP1 to evade the ER quality surveillance and transport on the cell surface more efficiently. The direct evidence supporting this hypothesis is that the LRP1 under EDEM3 deficiency showed slower mobility likely due to more mannoses that evaded from the trimming ([Figures 6](#fig6){ref-type="fig"}A and [7](#fig7){ref-type="fig"}A), and there were more mannoses on the cell surface of HepG2 EDEM3 KO cells ([Figure 6](#fig6){ref-type="fig"}C).

All three EDEM members were reported to have the mannosidase activity lately ([@bib16], [@bib41]). It is not clear, however, how the apparently redundant enzymes function differentially in the ER mannose trimming. Our genetic and mechanistic studies here provide some clues that EDEM3 plays more important roles than previously thought. Nevertheless, EDEM3 has some unique structural features that are missing in the other members. It has a PA domain and an ER retrieval signal ([Figure 2](#fig2){ref-type="fig"}C) ([@bib31]). The ER signal may constantly keep EDEM3 in the ER lumen. Interestingly, the P746S mutation is exactly located at the PA domain of EDEM3 coding region ([Figure 2](#fig2){ref-type="fig"}C). Notably, many proteases have the PA domains in their noncatalytic regions, which bear high homology in the domain sequences ([@bib24]). Although little is known about this domain of EDEM3, studies from other PA-containing proteases suggest that these domains play important roles in determining the protein functions such as in substrate targeting and autoinhibitor. Thus, EDEM3 could be the only mannosidase that targets specific protein substrates in the compartment of ER, although more work need to be done to clarify the mechanism.

Our studies indicate that the deletion of EDEM3 gene did not alter the cellular response to the induced ER stress *in vitro* ([Figure S8](#mmc1){ref-type="supplementary-material"}), suggesting that under normal growth condition, there might not be many misfolded proteins accumulated in the ER of the KO cells when compared with the WT cells. This may reflect that the change of gene expression resulted from the EDEM3 gene deletion. We observed that the expression of the genes responsible for cellular metabolic pathways was down-regulated, whereas the expression of the genes involved in the RNA and ER protein processing and transport was up-regulated. These gene expression changes may be able to compensate any defects in the ER caused by the loss of EDEM3 protein. However, the expression of the downstream genes regulated by unfolded protein response (UPR) pathways is virtually no different between the KO and WT cells. For instance, no significant changes were found for the expression of the transcription factor ATF6 and its target genes such BiP, protein disulfide isomerase, and glucose-regulated protein 94, which are the key ER-resident proteins for protein folding ([@bib4], [@bib45]). Additionally, in a typical UPR, the mRNA translation is inhibited to reduce the protein loading in the ER under ER stress. In this case the mRNA and protein production was up-regulated in the EDEM3 KO cells. Thus, the gene expression change may not be related to UPR. The increased RNA and protein production may be the response of the KO cells to compensate the reduced capacity in the protein processing due to the EDEM3 deficiency.

Genetic factors contribute to over 20% of the inter-individual variation of human plasma metabolites ([@bib11], [@bib36]). Given the key roles of metabolites as markers and effectors in cardiovascular diseases, it has become increasingly important to interrogate machineries and mechanisms behind the metabolite variations from population-based cohorts via genetic and biological studies. In this study, we leveraged human metabolomics data in over 1,500 individuals. We compared the association of EDEM3 P746S plasma lipid metabolite profile with the corresponding cellular pattern of the EDEM3 KO cells. They are largely correlated, suggesting that the up-regulated LRP1-mediated TGL uptake may have a major impact on the human TG phenotype. Although further studies are needed to obtain a broad spectrum of human plasma metabolite data and expand the studies on the functions of EDEM3 in regulating the cellular lipid metabolism, our study provides an example of how human genetic, functional and mechanistic, and human metabolomics studies can be emphasized for a broad biological insight with respect of disease pathogenesis of a gene.

In summary, in this study, by using a population-based genetic approach, we first demonstrated that a missense mutation in the coding region of EDEM3 is significantly associated with lower plasma TG in a large association study. We then performed both *in vitro* and *in vivo* functional analyses by either deleting EDEM3 gene in human hepatoma cell lines or hepatic EDEM3 KD in mice. We observed that the inhibition of EDEM3 expression increased LRP1 expression, which in turn induced TGL uptake and further reduced the plasma TG level. Finally, our metabolomics analysis indicates that EDEM3 deficiency increased cellular TG accumulation, which is inversely associated with the lipid metabolite profile of the plasma from the individuals carrying the EDEM3 alternate allele, suggesting that the LRP1-mediated TGL uptake plays a major role in the TG phenotype. Importantly, EDEM3 inhibition increased the expression of genes involved in the RNA and ER protein processing and transport, without altering the sensitivity of cells to ER stress, indicating that inhibition of EDEM3 expression could be potentially used as therapeutic approach to treat hypertriglyceridemia.

Limitation of the Study {#sec3.1}
-----------------------

Although multiple lines of evidence including from human genetics, *in vitro* cell, *in vivo* mouse models, and human metabolomics were provided to validate the roles of EDEM3 in regulating LRP1 expression, further studies are needed to obtain more mechanistic insight about this regulation. It will be especially important to investigate the correlation of EDEM3 inhibition with increasing LRP1 expression and reducing blood TG level for targeting EDEM3 with the goal of TG-lowering treatments. Our *in vivo* data from the mouse work only displayed modest impact on the TG level largely due of the limited reduction in EDEM3 expression from CRISPR gene silencing. We would expect stronger effect on TG lowering if substantial reduction in EDEM3 expression is obtained. Our human metabolomics data were obtained only from the limited number of individuals carrying the EDEM3 mutation with blood lipid metabolite measurements. Expanding the human genetic study together with lipid metabolomics on EDEM3 would shed broader insight about the regulation of EDEM3 in lipid metabolism at the population level, which would enable us to understand how the regulation correlates with the mechanistic data from *in vitro* and *in vivo* analyses.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The RNA-seq data presented in this article are deposited in Gene Expression Omnibus (GEO). The accession number for the datareported in this paper is GSE146070. The link to the data is at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146070>.
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